pharma news, views and analysis

in News
Keytruda gets okay from FDA for adjuvant melanoma
February 20, 2019 Share
X
Keytruda gets okay from FDA for adjuvant melanoma
https://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
in News
Cipla taps Wellthy for digital therapeutics expertise
February 19, 2019 Share
X
Cipla taps Wellthy for digital therapeutics expertise
https://pharmaphorum.com/news/cipla-taps-wellthy-for-digital-therapeutics-expertise/

Latest News

Merck/Pfizer up the pressure on BMS in first-line kidney cancer

The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney

Merck/Pfizer up the pressure on BMS in first-line kidney cancer

https://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/

Gilead NASH drug fails late stage trial

Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a

Gilead NASH drug fails late stage trial

https://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

See all

Views & Analysis

Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?

Drug development can be quite a risky business at the best of times, but particularly in the biotech

Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?

https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/

Changing hearts

Danish biotech Acesion Pharma is hoping to change the standard of care in atrial fibrillation. Richard Staines spoke

Changing hearts

https://pharmaphorum.com/views-and-analysis/changing-hearts/

The happiness factor

As part of pharmaphorum’s Eye on Innovation series, Richard Staines spoke to John Zibert, chief medical officer at

The happiness factor

https://pharmaphorum.com/r-d/views-analysis-r-d/happiness-factor-dermatological-conditions/

See all

Debates & Insights

Navigating new frontiers: Ways to find space in the future RA market

Overview Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15

Navigating new frontiers: Ways to find space in the future RA market

https://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/

Understanding blockchain – a practical guide for life sciences companies

Within the life science industry, uptake of blockchain is in the early stages, but with investment levels in

Understanding blockchain – a practical guide for life sciences companies

https://pharmaphorum.com/digital/insights-digital/understanding-blockchain-life-sciences/

Marketing science – brand innovation for pharma

Combining fields such as economics, statistics and operations research, marketing science has for some time operated under-the-radar as

Marketing science – brand innovation for pharma

https://pharmaphorum.com/debates-insight-sales-marketing/marketing-science-brand-innovation-for-pharma/

See all

Partner Content

Predictions for 2019: Ten trends that will shape the future of drug development and commercialization

eBook Provides Biopharma Decision Makers With What’s Next Insights to Navigate Challenges and Capitalize on the Opportunities Ahead

Predictions for 2019: Ten trends that will shape the future of drug development and commercialization

https://pharmaphorum.com/partner-content/press-releases/predictions-for-2019-ten-trends-that-will-shape-the-future-of-drug-development-and-commercialisation/

SMi’s 3D Cell Culture announces key industry speakers and agenda released

SMi’s 3d Cell Culture agenda released

SMi’s 3D Cell Culture announces key industry speakers and agenda released

https://pharmaphorum.com/partner-content/smis-3d-cell-culture-announces-key-industry-speakers-and-agenda-released/

SMi’s 10th Annual RNA Therapeutics Returns this February 2019

RNA Therapeutics 2019

SMi’s 10th Annual RNA Therapeutics Returns this February 2019

https://pharmaphorum.com/events/smis-10th-annual-rna-therapeutics-returns-this-february-2019/

See all

Search

Advanced Search

Trending